Clinical Analysis of Lamivudine combined with Traditional Medicines Fuzheng Huayu Capsule in the Treatment of Active Cirrhosis
This paper study and analyze the clinical effect of lamivudine combined with Fuzheng Huayu Capsule in the treatment of active cirrhosis. A total of 80 patients with active cirrhosis who were treated in our hospital from May 2017 to may 2018 were selected as research objects. All patients were divided into observation group and control group by random number method, 40 in each group. Patients in the control group took lamivudine tablets for treatment. Patients in the observation group took Fuzheng Huayu Capsule on the basis of the treatment in the control group, and patients in the two groups took blood clearing liver after treatment. Fibrosis index, child Pugh score, liver function, symptom improvement and adverse reactions. After treatment, the serum liver fibrosis index of the observation group was significantly better than that of the control group (P < 0.05); the child Pugh score and liver function of the observation group were significantly better than that of the control group (P < 0.05); the symptom improvement of the observation group was significantly better than that of the control group (P < 0.05); there was no significant adverse reaction after treatment in both groups. The treatment of active cirrhosis patients with lamivudine combined with Fuzheng Huayu capsule has a significant effect, which can significantly reduce the serum liver fibrosis index, effectively alleviate the liver function and clinical symptoms, improve the liver function of patients, and there is no obvious adverse reaction. It is worth popularizing in clinical treatment.